9 5 9 0 3
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
牛结核分枝杆菌 BCG 和结核分枝杆菌 H37Rv 中 EthAW21R 位点突变导致菌株对丙硫异烟胺和乙硫异烟胺交叉耐药
Authors Mugweru J, Liu J, Makafe G, Chiwala G, Wang B, Wang C, Li X, Tan Y, Yew WW, Tan S, Zhang T
Received 28 January 2018
Accepted for publication 20 March 2018
Published 13 June 2018 Volume 2018:11 Pages 891—894
DOI https://doi.org/10.2147/IDR.S163965
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Varun Dwivedi
Peer reviewer comments 2
Editor who approved publication: Dr Joachim Wink
摘要：乙硫异烟胺（Ethionamide, ETH）和丙硫异烟胺（prothionamide, PRO）在结核病的治疗方案中可以替换使用。异烟肼和丙硫异烟胺在敏感和耐药模式中生化和遗传信息层面的细微差别需要进一步的研究。我们首次报道了牛结核分枝杆菌 BCG 中一个新的位点突变（EthAW21R）与菌株对 PRO 和 ETH 的交叉耐药相关，我们的研究结果表明 EthAW21R 可以用作检测 PRO 和 ETH 交叉耐药的标记位点。
Keywords: mutation, EthAW21R, isoniazid, co-resistance, thioamides, molecular
marker
